

Clinical Trial Protocol

Iranian Registry of Clinical Trials

27 Jun 2026

Evaluation of the effect of Crocin on the serum levels of liver enzymes and Lipid Profile in patients with non-alcoholic fatty liver disease

Protocol summary

Study aim

Treatment of NAFLD patient by Crocin with low adverse effects

Design

A double blind randomized placebo-controlled trial of Crocin on patient with NAFLD.

Settings and conduct

Imam Hospital, Ahvaz

Participants/Inclusion and exclusion criteria

Inclusion criteria: both sexes, liver ultrasonography, high liver enzyme ALT and AST, >18 years old patient with NAFLD. Exclusion criteria: Viral and autoimmune liver diseases, metabolic liver disease, drug and alcohol consumption, pharmacotherapy in NAFLD.

Intervention groups

30 patients in the group receiving Crocin tablet (Krocina 15 mg) and 30 patients receiving placebo (maltodextrin) for 8 weeks.

Main outcome variables

Treatment of NAFLD and improvement of liver enzyme and lipid profile

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20180513039634N1**

Registration date: **2018-06-13, 1397/03/23**

Registration timing: **registered_while_recruiting**

Last update: **2018-06-13, 1397/03/23**

Update count: **0**

Registration date

2018-06-13, 1397/03/23

Registrant information

Name

Behnam Ghorbanzadeh

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 61 3391 3635

Email address

ghorbanzadeh.b@dums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2018-05-26, 1397/03/05

Expected recruitment end date

2018-08-21, 1397/05/30

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation of the effect of Crocin on the serum levels of liver enzymes and Lipid Profile in patients with non-alcoholic fatty liver disease

Public title

Effect of Crocin on non-alcoholic fatty liver disease

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

> 18 years old Patient with NAFLD (according to ultrasonography and high level of AST and ALT)

Exclusion criteria:

Viral and autoimmune hepatitis Metabolic liver disease, alcohol and drug consumption Pharmacotherapy for NAFLD

Age

From **18 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Outcome assessor
- Data analyser

Sample size

Target sample size: **60**

Randomization (investigator's opinion)

Randomized

Randomization description

Simple randomization

Blinding (investigator's opinion)

Double blinded

Blinding description

To maintain the double-blinded condition of the study design, labeled study medications using participant identification numbers. At the end of study, statistical analysis was performed using this data (unknown drug by statistics)

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Ahvaz Jundishapur University of Medical Sciences

Street address

No. 33, West kianpars, Streest 20

City

Ahvaz

Province

Khouzestan

Postal code

6155893814

Approval date

2018-02-24, 1396/12/05

Ethics committee reference number

IR.AJUMS.REC.1396.1014

Health conditions studied

1

Description of health condition studied

non-alcoholic fatty liver disease

ICD-10 code

K76.0

ICD-10 code description

Fatty (change of) liver, not elsewhere classified

Primary outcomes

1

Description

ALT

Timepoint

Before intervention and 8 weak after intervention

Method of measurement

Enzymatic photometry

2

Description

AST

Timepoint

Before intervention and 8 weak after intervention

Method of measurement

Enzymatic photometry

3

Description

TC, TG, LDL, HDL

Timepoint

Before intervention and 8 weak after intervention

Method of measurement

Enzymatic photometry

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: receiving one tablet containing 15 mg of Crocin (Samisaz Pharmaceutical Co.) daily with meal for 8 weeks.

Category

Treatment - Drugs

2

Description

Control group: receiving one tablet placebo (maltodextrin) daily with meal for 8 weeks.

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Imam Hospital

Full name of responsible person

Abazar Parsi

Street address

Imam Hospital, Naderi Street

City

Ahvaz

Province

Khouzestan

Postal code

6134914971

Phone

+98 61 3391 3635

Email

Ghorbanzadeh.b@dums.ac.ir

Full name of responsible person

Abazar Parsi

Position

Assistant professor

Latest degree

Subspecialist

Other areas of specialty/work

Internal Medicine

Street address

NO. 33, West kianpars, Street 20

City

Ahvaz

Province

Khouzestan

Postal code

6134914971

Phone

+98 61 3391 3635

Fax**Email**

b_ghorbanzadeh82@yahoo.com

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Ahvaz University of Medical Sciences

Full name of responsible person

Abazar parsi

Street address

Imam Hospital, Departement of internal medicine

City

Ahvaz

Province

Khouzestan

Postal code

6134914971

Phone

+98 61 3391 3635

Email

Ghorbanzadeh.b@dums.ac.ir

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Ahvaz University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Academic

Person responsible for general inquiries**Contact****Name of organization / entity**

Ahvaz University of Medical Sciences

Person responsible for scientific inquiries**Contact****Name of organization / entity**

Ahvaz University of Medical Sciences

Full name of responsible person

Abazar Parsi

Position

Assistant professor

Latest degree

Subspecialist

Other areas of specialty/work

Internal Medicine

Street address

NO. 33, West kianpars, Street 20

City

Ahvaz

Province

Khouzestan

Postal code

6134914971

Phone

+98 61 3391 3635

Fax**Email**

b_ghorbanzadeh82@yahoo.com

Person responsible for updating data**Contact****Name of organization / entity**

Ahvaz University of Medical Sciences

Full name of responsible person

Abazar Parsi

Position

Assistant professor

Latest degree

Subspecialist

Other areas of specialty/work

Internal Medicine

Street address

NO. 33, West kianpars, Street 20

City

Ahvaz

Province

Khouzestan

Postal code

6134914971

Phone

+98 61 3391 3635

Fax

Email

b_ghorbanzadeh82@yahoo.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to

make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available